声明：抗利尿激素分泌与帕金森病患者普拉克索相关综合征。
Retraction: Syndrome of Inappropriate Antidiuretic Hormone Secretion Associated with Pramipexole in a Patient with Parkinson's Disease.
我们通过本研究探讨了新型的D3受体激动剂普拉克索和罗匹尼罗对神经营养因子的调节作用和其对DA神经元的保护作用。
The present study discussed that the new D3 receptor agonists, pramipexole and ropinirole, mediate neurotrophic effects on DA neurons in fetal rat ventral mesencephalic cultures.
治疗症状波动的帕金森病患者时，持续的给予罗替戈汀透皮贴片贴敷治疗（6个月以上的治疗）可达到与口服普拉克索治疗相似的疗效。
Continuous delivery of rotigotine as transdermal patches could offer similar efficacy to oral pramipexole in patients with fluctuating Parkinson's disease over 6 months of treatment.
治疗症状波动的帕金森病患者时，持续的给予罗替戈汀透皮贴片贴敷治疗（6个月以上的治疗）可达到与口服普拉克索治疗相似的疗效。
Continuous delivery of rotigotine as transdermal patches could offer similar efficacy to oral pramipexole in patients with fluctuating Parkinson's disease over 6 months of treatment.
应用推荐